Dr Reddy's Laboratories announced on Wednesday that the price of its cardiovascular drug Cidmus has been slashed. The medication is a combination of sacubitril and valsartan that is prescribed to people who have heart failure.
Cidmus tablets are available in three strengths: 50mg, 100mg, and 200mg, and should be taken twice a day.
Cidmus will now be priced at Rs29 for 50 mg (down from Rs78.32), Rs49 for 100 mg (down from Rs83.86), and Rs79 for 200 mg (down from Rs96.71) per tablet, according to a statement from the Hyderabad-based drugmaker.
This price cut will broaden access to this trusted and well-established brand, it added.
In 2022, Dr Reddy's acquired Novartis AG's Cidmus brand for the Indian market.
At around 10.10 AM, Dr Reddy’s was trading 0.12% lower at Rs4,359.10 per piece, against the previous close of Rs4,364.35 on NSE. The counter hit an intraday high and low of Rs4,383.15 and Rs4,353.50 respectively.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
